Drug Trial Radar · NCT03100149
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
316
Actual
Start
Jun 27, 2017
Primary completion
Nov 27, 2019
Study completion Dec 1, 2031
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Prothena Biosciences Limited
- First posted
- Apr 4, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2). Participants who complete Part 2 (including the 12-week treatment-free follow up visit assessing long term safety and efficacy of RO7046015) will be offered participation in Part 3 open-label extension (all-participants-on-RO7046015-treatment) for an additional 520 weeks.
Conditions
- Parkinson's Disease
Interventions
RO7046015Drug
RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (\>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (\<) 65 kg.
RO7046015Drug
RO7046015 will be administered at dose of 1512 mg to all participants in the indicated arm.
PlaceboDrug
RO7046015 placebo will be administered to all participants in the indicated arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score (Sum of Parts I, II, and III) at Week 52Time frame: From baseline to Week 52
Locations
55 sites in 5 countries. Site status is shown where the registry gives one.
Uab Medicine
Birmingham, Alabama
Barrow Neurology Clinics
Phoenix, Arizona
Neurology Center of North Orange County
Fullerton, California
USC Keck Medical Center of USC
Los Angeles, California
University of California at San Francisco
San Francisco, California
CenExel Rocky Mountain Clinical Research, LLC
Englewood, Colorado
Associated Neurologists of Southern CT PC
Fairfield, Connecticut
Molecular Neurolmaging
New Haven, Connecticut
Aventura Neurologic Associates
Aventura, Florida
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida
USF Parkinsons Disease and Movement Disorders Center
Tampa, Florida
Northwestern University
Evanston, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Quest Research Institute
Farmington Hills, Michigan
Corewell Health Neurology and Epilepsy - Beltline
Grand Rapids, Michigan
Henry Ford Health System
West Bloomfield, Michigan
Columbia University
New York, New York
University of Rochester Medical Center
Rochester, New York
The Movement Disorder Clinic of Oklahoma
Tulsa, Oklahoma
Oregon Health & Science Uni
Portland, Oregon
UNIVERSITY of PENNSYLVANIA
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
Baylor College
Houston, Texas
Central Texas Neurology Consultants
Round Rock, Texas
University of Vermont Medical Center
Burlington, Vermont
Medizinische Universität Innsbruck
Innsbruck, Austria
Groupe Hospitalier Pellegrin
Bordeaux, France
Hopital Gabriel Montpied
Clermont-Ferrand, France
Hopital Henri Mondor
Créteil, France
Hôpital Michallon - Centre d'Investigation Clinique
Grenoble, France
hopital de la Timone
Marseille, France
CHU de Nice Hopital Pasteur
Nice, France
Hopital Pitie-Salpetriere APHP
Paris, France
CHU Poitiers
Poitiers, France
CHU Rouen Charles Nicolle
Rouen, France
CHU de Nantes - Hopital Laennec
Saint-Herblain, France
CIC - Hôpital Purpan
Toulouse, France
Klinik fur Neurologie
Berlin, Germany
Heinrich-Heine Universitätsklinik Düsseldorf
Düsseldorf, Germany
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.